Status:
COMPLETED
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
Lead Sponsor:
EMD Serono
Conditions:
Parkinson's Disease
Dyskinesia
Eligibility:
All Genders
30+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to test multiple doses of sarizotan to establish a dose with maximal safety and efficacy for treating treatment associated dyskinesia in Parkinson's disease participants.
Eligibility Criteria
Inclusion
- The participant is an out-patient
- The participant presents with a diagnosis of idiopathic Parkinson's disease
- Prior therapy with all registered Parkinsonian medication is allowed
Exclusion
- (For female participants) The participant is pregnant or lactating
- The participant is participating in another clinical study or has done so within the past 30 days
- The participant has received neurosurgical intervention related to Parkinson's disease
- The participant has relevant renal impairment
- The participant has relevant hepatic impairment
- The participant is suffering from any dementia or psychiatric illness
- The participant has a history of allergic asthma
Key Trial Info
Start Date :
September 30 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 31 2006
Estimated Enrollment :
398 Patients enrolled
Trial Details
Trial ID
NCT00105521
Start Date
September 30 2004
End Date
March 31 2006
Last Update
April 2 2018
Active Locations (32)
Enter a location and click search to find clinical trials sorted by distance.
1
Phoenix, Arizona, United States, 85004
2
Phoenix, Arizona, United States, 85013
3
Phoenix, Arizona, United States, 85032
4
Scottsdale, Arizona, United States, 85259